You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

220 Results
Blog posts

Blog Category: Insights & Perspectives

This past spring I was giving a talk about the My CancerIQ risk assessment tool at one of Ontario’s largest primary care conferences. And, as I so...
Jan 2019
Guidelines and Advice
Status: In-Review
ID: RR 21-5
Version: n/a
Jan 2019
Blog posts

Blog Category: Our Partners and the System

Anyone who has lived with a diagnosis of cancer or has supported a loved one through treatment knows the toll that the illness can carry. Travelling...
Dec 1969
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Selinexor and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    selinexor - In combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
dexamethasone,
selinexor
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
bosutinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Document
Dec 1969
Document
Dec 1969

Pages